SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

CervoMed Inc. – ‘8-K’ for 4/4/24

On:  Thursday, 4/4/24, at 7:00am ET   ·   For:  4/4/24   ·   Accession #:  1437749-24-10998   ·   File #:  1-37942

Previous ‘8-K’:  ‘8-K’ on / for 3/28/24   ·   Next:  ‘8-K’ on 4/5/24 for 4/1/24   ·   Latest:  ‘8-K’ on 4/23/24 for 4/22/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/04/24  CervoMed Inc.                     8-K:7,9     4/04/24   11:156K                                   RDG Filings/FA

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     30K 
 6: R1          Document And Entity Information                     HTML     46K 
 8: XML         IDEA XML File -- Filing Summary                      XML     12K 
11: XML         XBRL Instance -- crvo20240403_8k_htm                 XML     14K 
 7: EXCEL       IDEA Workbook of Financial Report Info              XLSX      8K 
 3: EX-101.DEF  XBRL Definitions -- crvo-20240404_def                XML     37K 
 4: EX-101.LAB  XBRL Labels -- crvo-20240404_lab                     XML     47K 
 5: EX-101.PRE  XBRL Presentations -- crvo-20240404_pre              XML     36K 
 2: EX-101.SCH  XBRL Schema -- crvo-20240404                         XSD     14K 
 9: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    19K 
10: ZIP         XBRL Zipped Folder -- 0001437749-24-010998-xbrl      Zip     14K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C: 
 i false  i 0001053691 0001053691 2024-04-04 2024-04-04


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

 
FORM  i 8-K
 

 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
 
 i April 4, 2024
Date of Report (Date of earliest event reported)
 

 
 i CervoMed Inc.
(Exact name of registrant as specified in its charter)
___________________________
 
 i Delaware
   
 i 30-0645032
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification No.)
 
   
 i 20 Park Plaza, Suite 424
 i Boston,  i Massachusetts
 
 i 02116
(Address of principal executive offices)
 
(Zip Code)
 
Registrants telephone number, including area code: ( i 617)  i 744-4400
 
Not applicable
(Former name or former address, if changed since last report)
___________________________
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 i 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 i 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 i 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 i 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Title of each class
 
Trading
Symbol(s)
 
Name of each exchange
on which registered
 i Common Stock, $0.001 par value
 
 i CRVO
 
 i NASDAQ Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company  i 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 

 
Item 7.01                  Regulation FD Disclosure
 
Corporate Presentations
 
Certain information concerning the business, clinical studies, development plans, financial position and related matters of CervoMed Inc. (the “Company” or “us”) has been made available on our website, www.cervomed.com, under the heading, “Investors – Events and Presentations.” Representatives of the Company may use this presentation, in whole or in part, and possibly with non-material modifications, periodically in connection with conferences, meetings, and presentations to investors, analysts and others.
 
The information contained in the presentation is summary information that is intended to be considered in the context of the Company’s filings with the Securities and Exchange Commission (“SEC”) and other public announcements that we may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in the presentation except as required by applicable law, although the Company may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, or through other public disclosure.
 
The Company makes no admission or representation as to the materiality of any information in the presentation or otherwise contained in Item 7.01 of this Current Report on Form 8-K. The information in this Item 7.01 (including any information incorporated herein by reference) is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of Section 18 of the Exchange Act unless we specifically incorporate it by reference in a document filed under the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as set forth by specific reference in such a filing.
 
Item 9.01         Financial Statements and Exhibits
 
(d)         Exhibits
 
Exhibit No.
 
Description
104
 
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
CervoMed Inc.
By:
Name:
Title: 
General Counsel
         
 
3

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on / For Period end:4/4/24None on these Dates
 List all Filings 
Top
Filing Submission 0001437749-24-010998   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., May 14, 8:17:36.2pm ET